Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL

NCT06410976 is registered in ClinicalTrials.gov with QED Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT06410976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06410976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL
Lead sponsor
QED Therapeutics, a BridgeBio company
Phase
Observational
Overall status
Recruiting
Start date
June 5, 2024
Completion date
October 31, 2026
Enrollment
150 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hypochondroplasia